Scinai Immunotherapeutics Ltd. announced that Ayana Pharma Ltd. signed a five-year Master Service Agreement (MSA) with the Company's CDMO business unit, Scinai Bioservices. Under the MSA, Scinai will provide drug development and cGMP manufacturing services, including aseptic filling and quality assurance, to Ayana, including encapsulating drug substances of various partners of Ayana into Ayana's proprietary liposomal drug delivery system. The agreement is anticipated to provide Scinai with at least $1.8 million in revenues over the next five years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.455 USD | -3.19% | +1.34% | -23.58% |
1st Jan change | Capi. | |
---|---|---|
-23.58% | 2.05M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- SCNI Stock
- News Scinai Immunotherapeutics Ltd.
- Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services